Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

Elena Bekerman,1 Gregory Neveu,1 Ana Shulla,2 Jennifer Brannan,3 Szu-Yuan Pu,1 Stanley Wang,1 Fei Xiao,1 Rina Barouch-Bentov,1 Russell R. Bakken,3 Roberto Mateo,4 Jennifer Govero,5 Claude M. Nagamine,6 Michael S. Diamond,7 Steven De Jonghe,7 Piet Herdewijn,7 John M. Dye,2 Glenn Randall,2 and Shirit Einav1

1Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. 2Department of Microbiology, University of Chicago, Chicago, Illinois, USA. 3US Army Medical Research Institute of Infectious Diseases, Viral Immunology Branch, Frederick, Fort Detrick, Maryland, USA. 4Department of Genetics and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. 5Departments of Medicine, Molecular Microbiology, and Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA. 6Department of Comparative Medicine, Stanford University School of Medicine, Stanford, California, USA. 7Laboratory of Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Global health is threatened by emerging viral infections, which largely lack effective vaccines or therapies. Targeting host pathways that are exploited by multiple viruses could offer broad-spectrum solutions. We previously reported that AAK1 and GAK, kinase regulators of the host adaptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying mechanism and relevance to other viruses or in vivo infections remained unknown. Here, we have discovered that AP1 and AP2 cotrafﬁc with HCV particles in live cells. Moreover, we found that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and infectious virus production. In cultured cells, treatment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or with more selective compounds inhibited intracellular trafﬁcking of HCV and multiple unrelated RNA viruses with a high barrier to resistance. In murine models of dengue and Ebola infection, sunitinib/erlotinib combination protected against morbidity and mortality. We validated sunitinib- and erlotinib-mediated inhibition of AAK1 and GAK activity as an important mechanism of antiviral action. Additionally, we revealed potential roles for additional kinase targets. These ﬁndings advance our understanding of virus-host interactions and establish a proof of principle for a repurposed, host-targeted approach to combat emerging viruses.

Introduction

A major threat to human health is posed by emerging viruses, such as dengue (DENV) and Ebola (EBOV). Dengue is estimated to infect 390 million people annually in over 100 countries (1). Dengue fever can progress to a life-threatening disease, known as severe dengue, particularly upon a secondary infection with a heterologous DENV strain. Consequently, development of a dengue vaccine has been hampered by the necessity to generate simultaneous protective immunity against 4 distinct DENV serotypes (2). As a further challenge, recent studies have suggested that preexisting DENV immunity may enhance Zika virus (ZIKV) infection and vice versa, and consequently increase disease severity (3–5). While an Ebola vaccine has shown promise recently (6), it is not yet approved. Moreover, no effective antiviral treatment is available against DENV, EBOV, ZIKV, and most other emerging viral pathogens, leaving the global population at risk for signiﬁcant morbidity and mortality.

Most antiviral therapies approved to date target viral enzymes (e.g., protease or polymerase) via a “one drug, one bug” approach. This approach has demonstrated measurable success in treating chronic viral infections, such as hepatitis C virus (HCV). However, such an approach to drug development is inefficient, expensive, and, therefore, not easily scalable to address the large unmet clinical need (7). Moreover, targeting virally encoded factors by monotherapy often is associated with rapid emergence of drug resistance (7). One alternative approach to treating viral infections while increasing the barrier to resistance is to target host functions, which the viruses intimately rely on (7). Moreover, focusing on host factors commonly required by multiple viral pathogens could provide broad-spectrum coverage. The host-targeted approach is attractive, particularly for the treatment of emerging viral infections lacking any treatment, given the opportunities to repurpose already existing drugs that are known to modulate speciﬁc host functions with tolerable side effect and toxicity proﬁles.

Intracellular membrane trafﬁc is one of many cellular processes hijacked by viruses. Membrane trafﬁc relies, in part, on the interactions between adaptor protein complexes (AP1 through AP5) and the transmembrane cargo. The well-characterized clathrin-associated APs, AP1 and AP2, are heterotetrameric complexes, which orchestrate the formation of vesicles destined for bidirectional transport in the secretory pathway and for endocytosis from the plasma membrane, respectively (8). The 2 host cell kinases AP2-associated protein kinase 1 (AAK1) and cyclin G–associated kinase (GAK) regulate
The Journal of Clinical Investigation

RESEARCH ARTICLE

1339
jci.org   Volume 127   Number 4   April 2017

vivo functional relevance remain unknown. In the present study, we demonstrate a role for AAK1- and GAK-regulated AP1 activity in HCV release and document that HCV particles specifically cotraffic with AP1 and AP2 in live cells. We also show a requirement for AAK1 and GAK in the life cycles of DENV and EBOV. Furthermore, we provide support for the feasibility of repurposing sunitinib/erlotinib combination as a broad-spectrum antiviral approach using in vitro models of multiple viral infections and murine models of DENV and EBOV. Lastly, we characterize the mechanism of action of sunitinib and erlotinib by validating AAK1 and GAK as critical mediators of the antiviral effect and revealing additional potential antiviral host targets, which include AXL receptor tyrosine kinase (AXL), KIT proto-oncogene receptor tyrosine kinase (KIT), and the proto-oncogene RET.

Results
APs cotraffic with HCV and orchestrate infection. To determine the differential roles of AP1 and AP2 in HCV infection, we examined the effect of depleting their μ subunits in Huh7.5 human hepatoma receptor-mediated endocytosis and trans-Golgi network (TGN) transport (9–12). Specifically, AAK1 and GAK phosphorylate the μ subunits of AP1 and AP2, thereby enhancing their binding affinity for sorting motifs within the cargo (9, 10, 13–15). Moreover, GAK recruits clathrin-associated APs to the plasma membrane and TGN (16).

Other groups have implicated APs in the life cycle of multiple unrelated viruses (17–26), and we reported roles for AP2 in HCV entry and assembly (22, 23). Our work demonstrated that through AP2 phosphorylation, AAK1 and GAK regulate these temporally distinct steps of the HCV life cycle, thereby, for the first time, uncovering their role as “master regulators” of a viral infection (22, 23). Moreover, we reported that sunitinib and erlotinib, approved anticancer drugs with potent binding to AAK1 and GAK (dissociation constant \( K_D \) of 11 and 3.1 nM, respectively; ref. 27), or selective, chemically distinct GAK inhibitors, block HCV entry and assembly in tissue culture (22, 23, 28). Although clathrin APs are presumed to mediate intracellular viral trafficking, this hypothesis has not been addressed in live cells. Moreover, the roles of AAK1 and GAK in viral infections beyond HCV and their in

Figure 1. AP1 and AP2 cotraffic with HCV and orchestrate infection. (A) Confirmation of gene expression knockdown by Western blot in Huh7.5 cells stably expressing AP shRNA or nontargeting control (NT). (B) Entry of HCV pseudoparticles (HCVpp) was measured by luciferase assays at 48 hours after infection. (C) HCV RNA replication measured via luciferase assays 72 hours after HCV RNA electroporation. (D) HCV infectivity measured via luciferase assays by inoculation of naïve cells with lysates (intracellular) and supernatants (extracellular) from electroporated cells. (E) AP1 ectopic expression following transfection of Huh7.5 cells with GLuc-tagged WT, T144A AP1, or an empty control; blotted with anti-GLuc antibody. (F) HCV intra- and extracellular infectivity in AP1-overexpressing cells versus control. Shown are means ± SD (n = 3–10). (G) Representative live cell fluorescence microscopy montages of TC-core HCV (green) cotrafficking with AP1- and AP2-mCherry (red). Distance traveled (μm) and time elapsed (min:s) during video acquisition are indicated. (H) Quantification of motile TC-core puncta cotrafficking with AP1, AP2, and LC3. (I) Quantification of distance traveled per acquisition of WT or Y136A mutant TC-core HCV associated with AP2. (J) Quantification of distance traveled per acquisition of TC-core HCV associated with AP1 or AP2 upon treatment with sunitinib (4 μM) and erlotinib (10 μM). Results in B–D and F represent data pooled from at least 2 independent experiments each with 6–10 biological replicates. H–J are representative experiments out of at least 3 conducted. Shown are means ± SD; **P < 0.001 relative to corresponding NT (B–D), empty vector control (F), WT TC-core (I), or vehicle control (J) by 1-way ANOVA, followed by Dunnett’s (B, D, and J) or Tukey’s (F) multiple comparisons test or 2-tailed unpaired t test (I).
The cellular infectivity was not affected by overexpression of either WT or T144A AP1 (Figure 1F). In contrast, extracellular infectivity increased upon ectopic expression of WT AP1 and decreased with ectopic expression of T144A AP1 (Figure 1F). Thus, viral release emerges as yet another step of the HCV life cycle, beyond entry and assembly, which is regulated by AAK1 and GAK.

While APs were postulated to directly mediate intracellular viral trafficking, this has never been addressed experimentally in live cells with any virus. To test the hypothesis that HCV particles shuttle with clathrin APs intracellularly, we used live cell imaging. The cotrafficking of individual, infectious HCV particles harboring a tetracysteine (TC) tag within the core protein (TC-core) with AP1- or AP2-mCherry was monitored (32). We previously have shown that TC-core motility requires HCV virion assembly (32).
Figure 3. Sunitinib and erlotinib have a synergistic anti-DENV effect and a high genetic barrier to resistance in vitro. (A) Chemical structures of the indicated drugs. (B and C) Cellular viability (blue) and dose response of overall DENV infection (black) to sunitinib and erlotinib measured by luciferase assays at 48 hours after infection. Data are plotted relative to vehicle control. (D and E) Synergy/antagonism at the 95% CI of sunitinib/erlotinib combination treatment on antiviral effect (D) and cellular viability (E) computed by MacSynergy II. (F) DENV4 was used to infect Huh7 cells and passaged every 72 hours by inoculation of naïve cells with equal volumes of viral supernatants under DMSO treatment or selection with sunitinib and erlotinib (SM + E) or SDM25N (DENV NS4B inhibitor) increasing from 0.5 to 2.5 μM over 8 passages. Viral titers were measured by plaque assays at every other passage. Dashed line represents assay detection limit. Results in (B) and (C) represent data pooled from at least 2 independent experiments. Data in (D–F) are representative of at least 2 experiments. Shown in (B, C, and F) are means ± SD. Individual experiments in (B–E) and (F) had 5–10 and 2 biological replicates, respectively.

Analysis of TC-core puncta stained with the biarsenical dye FIAsH revealed that a large fraction of motile TC-core cotrafficked with either AP1 (25%) or AP2 (38%), whereas only 3% cotrafficked with the autophagosomal marker LC3 (Figure 1, G and H, Supplemental Figure 1A, and Supplemental Videos 1–3; supplemental material available online with this article; https://doi.org/10.1172/JCI89857DS1). The velocities of the cotrafficking particles were consistent with previous reports on secretory vesicle trafficking as well as TC-core puncta cotrafficking with vesicle-associated membrane protein (VAMP) (refs. 32, 33, and Supplemental Figure 1B). AP2-associated TC-core puncta motility was reduced significantly upon mutation (Y136A) of a YxxΦ motif within core, a motif critical for AP2 binding and HCV assembly (22), as measured by the overall distance traveled (Figure 1I and Supplemental Video 4). These findings provide direct experimental evidence for a role of clathrin-associated APs in mediating intracellular virus trafficking. Specifically, these imaging data combined with our current and previous characterization of the roles of AP1 and AP2 in the life cycle of HCV (22, 23) support the hypothesis that AP1 cotraffics with HCV during viral release, while AP2 cotraffics with HCV during viral entry and subsequently to the sites of assembly.

To understand whether drug modulation of AP phosphorylation by AAK1 and GAK manifests itself in an intracellular trafficking defect, we studied the effect of sunitinib and erlotinib, approved drugs with potent anti-AAK1 and/or anti-GAK activity, on HCV particle trafficking by live cell imaging. Treatment of HCV-infected cells with sunitinib and erlotinib reduced motility of TC-core puncta cotrafficking with AP1 and AP2 (Figure 1J and Supplemental Videos 5–10). These findings support our hypothesis that the antiviral effect of sunitinib and erlotinib is associated with reduced intracellular viral traffic.

The role of AAK1 and GAK in DENV infection in cells. The requirement for AAK1 and GAK in viral infections beyond HCV is unknown. To investigate whether another, distantly related member of the Flaviviridae family relies on these regulatory kinases and their associated AP targets, we examined the effect of the corresponding gene silencing on DENV infection in human hepatoma (Huh7) cells. We observed a requirement for AP2, but not AP1, in DENV entry using cell lines stably expressing shRNA targeting AP1, AP2, or a nontargeting (NT) sequence (Figure 2, A and B). While depletion of AP1 and AP2 had no effect on DENV RNA replication as measured by subgenomic replicon assays (refs. 34 and Figure 2C), it diminished the production of infectious virus in culture supernatants (Figure 2D). Silencing expression of AAK1 and GAK resulted in no apparent cytotoxic effect (Figure 2, E and F) but, analogously to experiments with HCV, inhibited entry and infectious virus production of DENV, with no effect on RNA replication (Figure 2, G–I). These results implicate AAK1 and GAK in the DENV life cycle via regulation of 2 temporally distinct steps that depend on the clathrin-associated APs: entry and infectious virus production.

To determine whether a comparable effect on DENV infection can be achieved pharmacologically and further validate AAK1 and GAK as antiviral targets, we treated DENV-infected cells with selective AAK1 and GAK inhibitors. The imidazo[1,2-b]pyridazine-based compounds 7737 and 7745 were originally developed...
to modulate AAK1 activity as a potential treatment of neurologic disorders \( (K_{D} = 1 \text{ nM}, IC_{50} < 10 \text{ nM}) \) (Figure 2), Supplementary Figure 2, and ref. 38). The isothiazolo[5,4-b]pyridines 12g and 12i \( (\text{Figure 2K}) \) are potent \( (K_{D} = 8 \text{ nM}) \), selective, ATP-competitive GAK inhibitors capable of restricting HCV infection \( (28) \). We measured a dose-dependent inhibition of the DENV serotype 2 (DENV2) infection following a 2-day drug treatment with all 4 compounds, with half-maximal effective concentrations \( (EC_{50}) \) of 4.5–5.1 \( \mu \text{M} \) \( (\text{Figure 2, J and K}) \). The concentration range yielding at least 1 log reduction in viral infection showed minimal or no toxicity as measured by alamarBlue assays.

Together, these results validate AAK1 and GAK as regulators of DENV infection and point to their pharmacological inhibition as a potential anti-DENV strategy.

**Sunitinib and erlotinib have a synergistic anti-DENV effect and a high genetic barrier to resistance in vitro**. To determine whether a similar effect on DENV infection can be achieved with approved drugs with potent anti-AAK1 and/or anti-GAK activity, we treated DENV-infected cells with sunitinib and erlotinib \( (\text{Figure 3A}) \). Consistent with published HCV data \( (22, 23) \), we measured a dose-dependent inhibition of DENV2 infection following a 2-day drug treatment with an \( EC_{50} \) of 0.51 \( \mu \text{M} \) for sunitinib and 6.5 \( \mu \text{M} \) for erlotinib by luciferase assays \( (\text{Figure 3, B and C}) \). The concentration range yielding at least 2 log reduction in viral infection showed minimal or no toxicity as measured by alamarBlue assays with half-maximal cellular cytotoxicities \( (CC_{50}) \) of 8.0 \( \mu \text{M} \) for sunitinib and >50 \( \mu \text{M} \) for erlotinib \( (\text{Figure 3, B and C}) \) and Table 1). Similar results were demonstrated by standard plaque assays (Supplemental Figure 3A). Notably, treatment with combinations of the 2 drugs revealed synergistic inhibition of DENV2 infection with a synergy volume of 36.7 \( \text{mL}{^{2}}/\% \) at the 95% CI and no synergistic toxicity \( (\text{Figure 3, D and E}) \) and Supplemental Figure 3B). Importantly, sunitinib and erlotinib also dose-dependently inhibited infection of DENV1, DENV3, and DENV4 (Table 1).

To determine whether DENV can escape treatment with sunitinib and erlotinib, we passaged DENV in the presence of sunitinib/erlotinib combination or the DENV nonstructural (NS) 4B protein inhibitor SDM25N at increasing concentrations \( (0.5–2.5 \mu \text{M}) \) corresponding to values between \( EC_{50} \) and \( EC_{90} \). Infectious virus output was quantified over several passages by plaque assays. By passage 8, DENV4 overcame inhibition by SDM25N with the emergence of a previously characterized resistance mutation in NS4B \( (P101L, \text{analogous to P104L in DENV2}) \) \( (36) \). In contrast, DENV4 was cleared from the culture by passage 6 under the sunitinib/erlotinib treatment without any phenotypic resistance \( (\text{Figure 3F}) \). These results point to sunitinib/erlotinib combination as a potential anti-DENV strategy with a higher relative barrier to resistance than a direct-acting antiviral.

**Broad-spectrum activity of sunitinib and erlotinib**. Next, we studied the effect of sunitinib and erlotinib on replication of 2 additional flaviviruses, West Nile virus \( (\text{WNV}) \) and ZIKV. Sunitinib dose-dependently inhibited both WNV and ZIKV by focus-formation and plaque assays with \( EC_{50} \) of 0.51–0.55 \( \mu \text{M} \), whereas erlotinib demonstrated some efficacy only against ZIKV with \( EC_{50} \) of 6.28 \( \mu \text{M} \) (Supplemental Figure 4, A and B, and Table 1).

We also investigated whether EBOV, a member of an unrelated viral family \( (\text{Filoviridae}) \), whose entry depends on AP1 and AP2 activity \( (18, 37–39) \), may be similarly dependent on AAK1 and GAK. To test this hypothesis, we silenced AAK1 and GAK expression in Vero cells \( (\text{Figure 4A}) \) and measured infection of vesicular stomatitis virus encapsidated RNA \( (\text{encoding a GFP reporter gene}) \) pseudotyped with EBOV glycoproteins \( (\text{rVSV-GP EBOV}) \). Quantification of GFP-positive cells at the 20-hour time point by flow cytometry revealed that AAK1 and GAK depletion reduced infection relative to NT control \( (\text{Figure 4C}) \) without impacting cell viability \( (\text{Figure 4B}) \). A similar level of inhibition was observed upon quantification of viral RNA at 3 hours after infection, highlighting a defect in the entry step \( (\text{Supplemental Figure 5A}) \). These data further validate AAK1 and GAK as targets for broad-spectrum antiviral therapy. More-

### Table 1. Antiviral activity of sunitinib and erlotinib

<table>
<thead>
<tr>
<th>Family</th>
<th>Virus</th>
<th>Sunitinib EC_{50}/CC_{50} (\mu M)</th>
<th>Erlotinib EC_{50}/CC_{50} (\mu M)</th>
<th>Cells</th>
<th>Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flaviviridae</td>
<td>HCV J6/JFH</td>
<td>1.2/10</td>
<td>0.6/15</td>
<td>Huh7.5</td>
<td>Luciferase, FFA</td>
</tr>
<tr>
<td></td>
<td>DENV1 276RKR, PR54193</td>
<td>0.6/10</td>
<td>1.9/20</td>
<td>BHK-21</td>
<td>Plaque</td>
</tr>
<tr>
<td></td>
<td>DENV2 TSV01, 429557, New Guinea C</td>
<td>0.51/11.5</td>
<td>2.5/20–6.5/50</td>
<td>Huh7, BHK-21, Plaque</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DENV3 Philippines/H87/1956</td>
<td>0.3/10</td>
<td>1.3/20</td>
<td>BHK-21</td>
<td>Plaque</td>
</tr>
<tr>
<td></td>
<td>DENV4 BC287/97, H241</td>
<td>0.23/10</td>
<td>3.9/20</td>
<td>BHK-21</td>
<td>Plaque</td>
</tr>
<tr>
<td></td>
<td>WNV NY 99 3000.0259</td>
<td>0.55/20</td>
<td>NE</td>
<td>MEF, Vero</td>
<td>FFA</td>
</tr>
<tr>
<td></td>
<td>ZIKV MR766</td>
<td>0.51/14.1</td>
<td>6.28/30</td>
<td>Huh7</td>
<td>Plaque</td>
</tr>
<tr>
<td>Filoviridae</td>
<td>EBOV</td>
<td>0.47/10</td>
<td>12.9/30</td>
<td>Huh7</td>
<td>Immunostaining</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2.88/15</td>
<td>Vero</td>
<td>Plaque</td>
</tr>
<tr>
<td>Togaviridae</td>
<td>CHIKV 181/25</td>
<td>4.67/11.9</td>
<td>0.7/30</td>
<td>Vero</td>
<td>Plaque</td>
</tr>
<tr>
<td></td>
<td>Arenaviridae JUNV Candid1</td>
<td>4.8/10.4</td>
<td>1.7/20</td>
<td>Vero</td>
<td>CPE</td>
</tr>
<tr>
<td></td>
<td>Retroviridae HIV NL4-3</td>
<td>0.8/20</td>
<td>2/20</td>
<td>HeLa/T2M-b1</td>
<td>Luciferase</td>
</tr>
<tr>
<td></td>
<td>Paramyxoviridae RSV A2</td>
<td>&lt;0.12/2.5</td>
<td>&lt;0.12/30</td>
<td>Hep2</td>
<td>Immunoplaque</td>
</tr>
</tbody>
</table>

**EC_{50}**, half-maximal effective concentration; **CC_{50}**, half-maximal cellular cytotoxicity; **FFA**, focus-forming assay; **NE**, no effect; **CPE**, cytopathic effect. Virus abbreviations: **WNV**, West Nile virus; **CHIKV**, chikungunya virus; **JUNV**, Junin virus; **RSV**, respiratory syncytial virus. Each virus was tested at least twice with 3 or more technical replicates.
over, treatment of Vero cells with sunitinib and erlotinib resulted in a dose-dependent decrease in rVSV-GP EBOV infection measured by flow cytometry 20 hours after infection and entry measured by quantitative reverse transcriptase PCR (qRT-PCR) 3 hours after infection (Figure 4D and Supplemental Figure 5B). Although the effect of erlotinib measured by flow cytometry was modest relative to that of sunitinib, combination treatment displayed measurable synergy in inhibiting entry with a synergy volume of $147.05 \mu M^2\%$ at the 95% CI and zero synergistic toxicity (Figure 4, E and F). Next, we tested the ability of these drugs to inhibit authentic EBOV infection in Huh7 cells. Sunitinib treatment resulted in a dose-dependent reduction in EBOV infection with EC_{50} value of 0.47 $\mu M$ and CC_{50} greater than 10 $\mu M$, whereas erlotinib showed moderate activity with EC_{50} of 12.9 $\mu M$ and no appreciable cytotoxicity at the concentrations tested (Figure 4G and Table 1). Sunitinib/erlotinib combinations are effective in vivo. To address the therapeutic potential of sunitinib and erlotinib as antiviral agents, we tested their application in a murine model of dengue. We measured viral burden and mortality in an IFN-α/β and IFN-γ receptor–deficient murine model of dengue on 129/Sv (AG-129) (40, 41) and C57BL/6 (AG-B6) genetic backgrounds. In a prophylaxis model, we initiated once-daily treatment of AG-B6 mice with 30–60 mg/kg of sunitinib and erlotinib in combination or individually concurrently with DENV inoculation and analyzed viremia at 48 hours. The doses tested for each drug were at or near the equivalent of approved human dose as calculated based on the body surface area per the FDA’s guidelines (42). These doses were below the maximum tolerated dose (MTD) in mice and confirmed to be nontoxic in our dengue model (42–44). Treatment with erlotinib did not alter viremia, whereas sunitinib alone marginally reduced it (Figure 5A). Consistent with our in vitro synergy results, daily administration of the combination treatment resulted in 11-fold reduction in viral RNA (Figure 5A). In addition, we measured a significant reduction of the infectious virus load by plaque assays in the serum as well as spleen and liver in mice treated with 30 mg/kg doses of sunitinib and erlotinib relative to vehicle controls (Supplemental Figure 6A). Pharmacokinetic analysis revealed that within the first 6 hours of administration each drug concentration in the serum, as measured by liquid chromatography-tandem mass spectrometry, exceeded the

Figure 4. Inhibition of AAK1 and GAK suppresses EBOV infection. (A) Confirmation of siRNA-mediated gene expression silencing by quantitative PCR in Vero cells. Shown is normalized gene expression relative to GAPDH at 48 hours after transfection. (B and C) Relative cell viability measured by alamarBlue assays (B) and rVSV-GP EBOV infection of Vero cells measured by flow cytometry (C) at 20 hours after infection of AAK1- and GAK-depleted cells. **P < 0.001 relative to NT (1-way ANOVA followed by Dunnett’s multiple comparisons test). (D) Dose response of rVSV-GP EBOV infection to 4-hour treatment with inhibitors measured by flow cytometry at 20 hours after infection in Vero cells. (E and F) Synergy/antagonism of sunitinib/erlotinib combination treatment on rVSV-GP EBOV infection (E) and cell viability (F). (G) Dose response to drug treatment in Huh7 cells under biosafety level 4 containment following 48 hours with EBOV infection (black) measured by immunostaining with an anti-GP antibody, and cell viability (blue) measured by Hoechst counterstain and quantified by a high-content imager. Data are plotted relative to vehicle control. All data shown are representative of at least 2 experiments; B–G have 3 biological replicates each. Shown in B–D and G are means ± SD.
corresponding EC$_{50}$ concentration deduced from our in vitro data (Supplemental Figure 6B). Moreover, the synergy between sunitinib and erlotinib predicts even more potency in combination. Although sunitinib and erlotinib were largely cleared from the serum by 18 hours, which is in contrast with the slower clearance rates reported in humans (44, 45), both drugs concentrate severalfold within tissues where DENV replicates, such as liver (46, 47). To maintain higher serum drug concentration, we next administered 30 mg/kg drug combination at 12-hour intervals and measured viremia. The twice-daily drug administration resulted in an even more apparent reduction of viral load relative to vehicle control (Figure 5B). Notably, drug administration reduced viral load from day 2 to 3 postinfection in contrast to an increase in viral load within the control arm during that time.

To assess whether the reduction in viral load would translate into improved disease outcome, we determined the effect of combination treatment with sunitinib and erlotinib on morbidity and mortality in AG-129 and AG-B6 mice. Following infection with a lethal DENV inoculum, we initiated once-daily drug administration at a dose sufficient to significantly reduce viremia (i.e., 30 mg/kg of each drug). The animals were monitored twice daily and were euthanized when moribund (48). The experiment was...
treatment proved efficacious with either i.p. or oral administration, the latter of which is approved for use in humans (Figure 5, C and D). We also compared the effect of daily treatment with the individual drugs with that of the combination. In this trial, 94% of vehicle-treated AG-129 mice succumbed to infection; treatment with erlotinib did not alter survival, whereas sunitinib alone offered partial (37%) protection. Consistent with our in vitro synergy results, we observed the greatest protection (62%) from concluded when all the remaining animals regained full mobility and displayed weight gain for at least 2 consecutive days. Upon a 5-day drug treatment regimen given either i.p. or orally, we observed a significant reduction in morbidity and mortality of infected animals relative to vehicle controls (Figure 5, C and D). Specifically, 100% of vehicle-treated mice succumbed to infection on day 4–8 postinfection, whereas sunitinib/erlotinib treatment protected 75%–100% of the mice. This combination treatment proved efficacious with either i.p. or oral administration, the latter of which is approved for use in humans (Figure 5, C and D). We also compared the effect of daily treatment with the individual drugs with that of the combination. In this trial, 94% of vehicle-treated AG-129 mice succumbed to infection; treatment with erlotinib did not alter survival, whereas sunitinib alone offered partial (37%) protection. Consistent with our in vitro synergy results, we observed the greatest protection (62%) from...
GAK likely contributes to the anti-DENV effect of these drugs. This phenotype supports a hypothesis that inhibition of AAK1 and GAK, mediated by direct-acting antivirals (7), was not affected by these drugs. We detected interference precisely with the steps inhibited via siRNAs against AAK1 and GAK (Figure 6, A–C). Notably, DENV RNA replication, a step commonly inhibited by direct-acting antivirals (7), was not affected by these drugs. Given the observed potency of sunitinib and sunitinib/erlotinib combination against EBOV infection in vitro, we assessed in vivo efficacy of these drugs in a murine model of Ebola. Drugs were administered daily i.p. for 10 days beginning at 6 hours before infection. As with the dengue model, the chosen doses were at or near the equivalent of approved human dose, below the MTD in mice, and confirmed to be nontoxic in our Ebola model. All mice demonstrated signs of morbidity as evident by weight loss during the first 7–10 days after infection (Figure 5G). Ninety percent of vehicle-treated mice succumbed to infection on days 6–13 postinfection; treatment with sunitinib at 45 mg/kg did not alter animal survival, whereas 5 mg/kg sunitinib alone increased survival to 30% (Figure 5H). Consistent with our in vitro synergy results, we observed the greatest weight gain and survival (50%) with a combination drug treatment.

Together, these results demonstrate therapeutic potential of sunitinib/erlotinib combinations against infections with 2 unrelated emerging RNA viruses.

Mechanisms underlying the antiviral effects of sunitinib and erlotinib in vitro and in vivo. To better understand the target(s) and mechanism of action underlying the anti-DENV activity of sunitinib, we first probed the steps of the viral life cycle and act as broad-spectrum antivirals. As with the dengue model, the chosen doses were at or near the equivalent of approved human dose, below the MTD in mice, and confirmed to be nontoxic in our Ebola model. All mice demonstrated signs of morbidity as evident by weight loss during the first 7–10 days after infection (Figure 5G). Ninety percent of vehicle-treated mice succumbed to infection on days 6–13 postinfection; treatment with sunitinib at 45 mg/kg did not alter animal survival, whereas 5 mg/kg sunitinib alone increased survival to 30% (Figure 5H). Consistent with our in vitro synergy results, we observed the greatest weight gain and survival (50%) with a combination drug treatment.

Together, these results demonstrate therapeutic potential of sunitinib/erlotinib combinations against infections with 2 unrelated emerging RNA viruses.

Mechanisms underlying the antiviral effects of sunitinib and erlotinib in vitro and in vivo. To better understand the target(s) and mechanism of action underlying the anti-DENV activity of sunitinib, we first probed the steps of the viral life cycle and act as broad-spectrum antivirals. As with the dengue model, the chosen doses were at or near the equivalent of approved human dose, below the MTD in mice, and confirmed to be nontoxic in our Ebola model. All mice demonstrated signs of morbidity as evident by weight loss during the first 7–10 days after infection (Figure 5G). Ninety percent of vehicle-treated mice succumbed to infection on days 6–13 postinfection; treatment with sunitinib at 45 mg/kg did not alter animal survival, whereas 5 mg/kg sunitinib alone increased survival to 30% (Figure 5H). Consistent with our in vitro synergy results, we observed the greatest weight gain and survival (50%) with a combination drug treatment.

Together, these results demonstrate therapeutic potential of sunitinib/erlotinib combinations against infections with 2 unrelated emerging RNA viruses.

Mechanisms underlying the antiviral effects of sunitinib and erlotinib in vitro and in vivo. To better understand the target(s) and mechanism of action underlying the anti-DENV activity of sunitinib, we first probed the steps of the viral life cycle and act as broad-spectrum antivirals. As with the dengue model, the chosen doses were at or near the equivalent of approved human dose, below the MTD in mice, and confirmed to be nontoxic in our Ebola model. All mice demonstrated signs of morbidity as evident by weight loss during the first 7–10 days after infection (Figure 5G). Ninety percent of vehicle-treated mice succumbed to infection on days 6–13 postinfection; treatment with sunitinib at 45 mg/kg did not alter animal survival, whereas 5 mg/kg sunitinib alone increased survival to 30% (Figure 5H). Consistent with our in vitro synergy results, we observed the greatest weight gain and survival (50%) with a combination drug treatment.

Together, these results demonstrate therapeutic potential of sunitinib/erlotinib combinations against infections with 2 unrelated emerging RNA viruses.
approaches, we demonstrate roles for AP1 and AP2 complexes as well as AAK1 and GAK in entry and assembly/release of Flaviviridae family members and validate these host factors as attractive targets for broad-spectrum antiviral therapy (Figure 7). We establish that sunitinib and erlotinib inhibit DENV and EBOV infections in vitro and in vivo, and are potent in vitro against WNV, ZIKV, and RNA viruses from 4 additional families: Togaviridae, Arenaviridae, Paramyxoviridae, and Retroviridae. Together, our data illustrate the utility of these 2 clinically approved compounds both as tools to identify host factors important in viral infection and as potential therapies against emerging viral infections.

Using advanced live cell imaging, we provide the first direct evidence, to our knowledge, that viral particles cotraffick intracellularly with AP complexes. Our imaging findings exclude a theory whereby AP complexes contribute to viral infections solely by recruiting or mediating intracellular traffic of host cargo components essential for the viral life cycle.

We show that sunitinib and erlotinib, potent, albeit nonselective, inhibitors of AAK1 and GAK, respectively, repress DENV and EBOV infections in vitro and their combination reduces viremia, morbidity, and mortality in the relevant murine models. Replication assays demonstrating efficacy against viral species in 6 unrelated families (Table 1) further support our broad-spectrum hypothesis, though in vivo efficacy beyond dengue and Ebola remains to be tested. AAK1 and GAK have partially overlapping functions (12, 23), which may explain moderate antiviral effect in vitro with either sunitinib or erlotinib, yet synergistic activity upon treatment with both. The synergy also may result from inhibition of additional targets by these compounds. Although the observed reduction in DENV load was relatively modest in mice, it correlated with a significant survival benefit, comparable to the report on host α-glucosidase inhibitor celgosivir (51), which yielded 100% protection from mortality with less than 10-fold reduction in viremia. Importantly, the sunitinib/erlotinib combination remained protective in the mouse model of dengue even when administered after established infection, thereby supporting its promise as both prophylaxis and therapy.

We provide multiple lines of evidence to support modulation of AAK1 and GAK activity as an important mode of antiviral action of sunitinib and erlotinib in the dengue model. We demonstrate that these drugs inhibit both DENV entry and infectious virus production, analogous to the phenotype seen with RNAi-mediated suppression of clathrin-associated APs and AAK1 and GAK. Additionally, we demonstrate antiviral effects of more selective AAK1 and GAK inhibitors. Due to lack of affinity to most of sunitinib’s and erlotinib’s cancer targets (e.g., VEGFR and EGFR) (28, 35), the activity of the selective compounds further confirms that AAK1 and GAK are relevant antiviral targets. While the more selective GAK inhibitors also bind KIT, more work is required to validate whether KIT is an anti-DENV target. Furthermore, we characterized the mechanism by which the pharmacological inhibition of AAK1 and GAK mediates the anti-dengue effect. We establish that antiviral activity of sunitinib and erlotinib correlates with reduced phospho-AP2 levels in vitro. In accordance with this observation, we show that WT but not a phosphorylation AP2 mutant can rescue the anti-dengue effect of these drugs. We provide evidence that this mechanism also plays a role in vivo by demonstrating that antiviral activity correlates with reduced AP2 phosphorylation in tissues upon drug treatment. These findings reveal that a block in AP2 phosphorylation mechanistically explains at least in part the antiviral effect of AAK1 and GAK inhibitors. These findings also present AP2 phosphorylation as a useful pharmacodynamic biomarker in potential future clinical studies. We further demonstrate that sunitinib and erlotinib reduce HCV-AP1 and -AP2 cotrafficking by live cell imaging, thereby validating this mode of action at the molecular level. While AP-mediated intracellular membrane trafficking likely represents a primary mechanism by which AAK1 and GAK regulate viral infection, additional substrates of these kinases, such as NUMB, also may contribute to this function (23).

We explore the possible involvement of additional targets with K_50’s of 20 nM or less reported for sunitinib and erlotinib using a siRNA library against 27 kinases. Our siRNA screen reveals that none of the other major targets of erlotinib beyond GAK, namely EGFR and STK10, affect DENV infection. In contrast, at least 3 additional targets of sunitinib beyond AAK1, namely AXL, KIT, and RET, may facilitate DENV infection and thus potentially also mediate sunitinib’s antiviral effect. AXL is an already known attachment factor/signaling receptor for multiple RNA viruses, including DENV, EBOV, and possibly ZIKV (52–55). Although confirmatory studies with AXL-deficient cells are required, inhibition of AXL by sunitinib may contribute to its effect on DENV entry. KIT and RET are paralogs with no reported roles in RNA viral infections and await further investigation. Given our inability to silence expression of KIT without a substantial negative impact on cell viability (likely due to its role in cell survival and proliferation; ref. 56), its specific relevance to DENV infection remains unclear. Overall, our data underscore the utility of using sunitinib and erlotinib as pharmacological probes to identify novel host factors required for viral infection.

We speculate that inhibition of AAK1 and GAK accounts for these drugs’ effect against a broad spectrum of viruses, particularly those previously shown to depend on AP1 and AP2 activity, such as EBOV (18, 37–39). Inhibition of additional kinases including AXL, KIT, and RET may play a role. Though most of the EC_{50} values we report fall in the low micromolar range for the 6 viral families tested (Table 1), the relative potency of sunitinib and erlotinib varies between the different viral species. Such differences can be attributed to both variations in the assays used and the likely distinct dependence on the various host factors targeted by these inhibitors in the life cycle of different viruses. Other mechanisms of action, such as modulation of immune responses, also could contribute to the protective phenotype observed in vivo.

Although toxicity is a concern when targeting host functions, finding a safe therapeutic window may be feasible. Sunitinib and erlotinib each are approved as a once-daily oral treatment for multiple cancers at doses comparable to those exhibiting antiviral activity in vivo. A combination therapy already has been evaluated clinically and was tolerated, albeit with an increase in the adverse events primarily related to gastrointestinal disturbances (57, 58). However, a shift from the long-term treatment of cancer to acute infection such as with DENV should improve tolerance and minimize adverse effects. The safety and efficacy of sunitinib and/or erlotinib will be evaluated in dengue patients in the near future and potentially in patients with EBOV disease in future outbreaks (ClinicalTrials.gov NCT02380625).
The Journal of Clinical Investigation

The various genetic diversity of viral species and replication strategies challenges the design of broadly effective direct-acting antivirals; however, a host-targeted approach could circumvent this issue. Sunitinib and erlotinib inhibit all 4 DENV serotypes. Moreover, a broad-spectrum therapy, such as with sunitinib/erlotinib combination, could be used to treat DENV-CHIKV (59, 60) or DENV-ZIKV (61) co-infections and infections with newly emerging RNA viruses. It also can be administered even before an accurate diagnosis of a viral threat, thereby increasing protection. Furthermore, although viral resistant mutations can emerge during treatment with host-targeted approaches (62), targeting of host proteins that are not under the genetic control of viruses is more likely to have a higher barrier to resistance than classical direct-acting antivirals. This is exemplified by our data and treatment with cyclophilin inhibitors (63). We recognize, however, that our dengue resistance assay is somewhat limited by the short-term virus passage. Although we predict that the genetic barrier to resistance is high, it may be possible to select for resistance over longer-term passage under different conditions or in a different, chronic infection model. Lastly, viruses use strategies similar to those of cancer cells for overcoming drug-mediated inhibition. Simultaneous inhibition of several kinases or targeting of several pathways by the same drug or drug combination may prove attractive in combating viral pathogens, as previously shown in cancer (64). Such “polypharmacology” by a single drug could increase the effectiveness while minimizing viral resistance.

In summary, our study serves as a proof of concept for the feasibility of identifying novel host-targeted broad-spectrum antiviral therapies via both repurposing and development of novel chemical entities. Such approaches may provide additive and possibly synergistic effects in combination with other strategies being developed to combat emerging viral infections.

Methods

Plasmids and virus constructs. ORFs encoding AP1M1 (AP1) and AP2M1 (AP2) were selected from the Human ORFeome library of cDNA clones (65) (Open Biosystems) and recombined into either pCherry (for mCherry fluorescence protein tagging) or pGLuc (for Gaussia Princeps luciferase fragment [GLuc] tagging) vectors using Gateway technology (Invitrogen). GFP-LC3 construct was previously described (66). pFLj6/JFH(p7-Rluc2A) was a gift from Charles M. Rice (Rockefeller University, New York, New York, USA) (67). HCV TC-core was previously described (32). Plasmids used in the HCVpp entry assays (pNL4-3.Luc.R-E, pcDM8, and pLKO.1-puro nonmammalian shRNA control; Sigma-Aldrich) and ing lentivirus (TRCN0000218336, TRCN0000060239, or Mission were synthesized by ACME Bioscience Inc.

Western blotting and antibodies. Cells were lysed in M-Per protein extraction reagent (Thermo Fisher Scientific). For phosphoprotein detection, cells were pretreated with 100 nM calyculin A (Cell Signaling), a PPI and PP2a phosphatase inhibitor, for 30 minutes prior to lysis. Liver tissue was homogenized in RIPA buffer supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific) and 100 nM calyculin A using 0.9- to 2-mm stainless steel beads in a BBX24 Bullet Blender homogenizer (NextAdvance). Clarified protein lysates were run on 4%-12% Bis-Tris gels (Invitrogen), transferred onto PVDF membranes (Bio-Rad). Blots were blocked and blotted with anti-AP1M1 (Abcam, catalog ab111135), anti-AP2M1 (Abcam, catalog ab75995), anti-GLuc (New England BioLabs, catalog E802SS), anti-phospho-AP2M1 (T156) (Cell Signaling, catalog 3843S), anti-AAK1 (Abcam, catalog ab34971), anti-GAK (MBL International, catalog M057S), and anti-β-actin (Sigma-Aldrich, catalog A3854) antibodies. Signal was detected with HRP-conjugated secondary antibodies. Band intensity was quantified with ImageJ software (NIH). See complete unedited blots in the supplemental material.

RNA interference. siRNAs (100–250 nM) were transfected into cells using siPORTER (Millipore) 48 hours before infection. Sequences/catalog numbers are as follows: human AAK1 and GAK, Silencer Select predesigned siRNA ID##s22494 and s5529, respectively (Thermo Fisher Scientific); Chlorocrobus sabaeus (green monkey) AAK1 siRNA#1, GCAUAUGUGGUAACTCAGATT; AAK1 siRNA2, GAAUAUGGGUGUAUAGTT; GAK siRNA#1, CGCAUAAGAGGCUAUAACT; GAK siRNA#2, CAGCAUCUAGGAAAGATT; NT; Silencer Select negative control (Thermo Fisher Scientific, catalog 4390844). Infections were performed at 48 hours after transfection. APIM1 and AP2M1 were silenced via transduction with shRNA-expressing lentivirus (TRCN00000218336, TRCN0000060239, or Mission pl.KO.1-puro nonmammalian shRNA control; Sigma-Aldrich) and selection on 1 μg/ml puromycin. Custom Cherry-Pick ON-TARGETPlus siRNA library against 27 kinase genes was purchased from Dharmacon (see Supplemental Table 1 for gene and siRNA sequence details).

Virus production. HCV 2a J6/JFH(p7-Rluc2A) was transcribed in vitro using Megascript T7 kit (Ambion), and DENV2 TSV01, 16681 (used for DENV in vitro assays), or N124D/K128E DENV2 PLO46 (used for DENV in vivo infections) RNA was transcribed in vitro using mMessage/mMachine (Ambion) kits. HCVcc and HCVpp were produced as described previously (23). DENV was produced by electro-
poration of RNA into BHK-21 cells, harvesting of supernatants at day 10, and titering via standard plaque assays on BHK-21 cells. In parallel, on day 2 after electroporation, DENV-containing supernatant was used to inoculate C6/36 cells to amplify the virus. For in vivo experiments, DENV supernatant was concentrated 100-fold by centrifugation at 50,000 g. rSV-GP EBOV was propagated and titered on Vero cells via fluorescence-focus assay (69).

Entry assays. Huh7.5 cells were infected with HCVpp (71, 72) and 8 μg/ml Polybrene for 4 hours. Firefly luciferase activity was measured at 48–72 hours after infection. DENV2 entry was measured at 6 hours after infection of Huh7 cells by monitoring of Renilla luciferase activity. Luminescence was detected on InfiniteM1000 plate reader (Tecan). Vero cells were infected with rSV-GP EBOV for 3 hours, total RNA was harvested and reverse transcribed, and EBOV GP transcript was quantified by real-time PCR and normalized to GAPDH expression.

Infection assays. Huh7 cells were infected with DENV or ZIKV in replicates (n = 3–10) for 4 hours at MOI of 0.01. Overall infection was measured either at 48 hours using a Renilla luciferase substrate or at 72 hours by plaque assays. Vero cells were infected with rSV-GP EBOV for 4 hours and washed. At 20 hours after infection, cells were fixed with 4% formaldehyde and analyzed on an LSR II cytometer (BD Biosciences) using FITC channel. Data were processed using FlowJo software. EBOV infection was carried out under biosafety level 4 conditions. Forty-eight hours after infection, cells were formalin-fixed, and infection was measured by immunofluorescence using KZ52 anti-EBOV antibody in an Operetta HCS using the Harmony software package. Other viral infection assays, conducted by the Diamond lab (WNV), IBT Bioservices (CHIKV, RSV, JUNV), and the NIH/National Institute of Allergy and Infectious Diseases (others), were performed as summarized in Table 1.

RNA replication assays. HCV RNA replication was measured 72 hours after electroporation, as previously described (22). DENV2 replication assays were performed as previously described (34). Briefly, Huh7 cells were transfected with DNA-launched DENV2 replicon, pCMV-D2Rep along with TET-ON plasmids. Thirty-six hours after transfection, viral RNA transcription was induced by doxycycline and shut down by changing to doxycycline-free medium 6 hours later. Replication was monitored by luciferase activity every day for 3 days. Data were normalized to activity at 24 hours after induction.

Infectious virus production. Infectious HCV or DENV production (i.e., extracellular infectivity) was measured in culture supernatants of cells electroporated with viral RNA for 48–72 hours and used to infect naive cells for 48 hours. Intracellular HCV infectivity was measured by inoculation of naive cells with lysates of electroporated cells subjected to 4 rounds of free-thawing and clarified at 5,000 g, as previously described (22).

Pharmacological inhibition. For entry assays, cells were pretreated with the inhibitors or DMSO for 1 hour before and for the duration of the infection, followed by replacement with drug-free medium. For the overall infection, RNA replication, or infectious virus production assays, inhibitors were left in for the duration of the study.

Gain-of-function assays. WT or T156A AP2 or empty vector control was expressed ectopically in Huh7 cells by lentiviral transduction. Twenty-four hours after transduction, cells were pretreated with sunitinib and erlotinib, infected with luciferase reporter DENV at MOI of 0.01, and incubated for 72 hours prior to luciferase and viability assays.

Live cell imaging. Huh7.5 cells were infected with concentrated HCV TC-core (32) at MOI of 1 for 24 hours, then transfected with either AP1- or AP2-mCherry using Lipofectamine 2000 (Invitrogen) and seeded onto collagen-coated 35-mm fluorodishes (World Precision Instruments). At 72 hours after infection, cells were labeled with biarsenical dye (1.25 μM) in Opti-MEM at 37°C for 30 minutes, then washed 3 times with 1X BAL (2,3-dimercapto-1-propanol) wash buffer (Invitrogen) supplemented with 500 μM 1,2-ethanediol in Opti-MEM. The cells were washed and incubated in prewarmed imaging media (DMEM-F12; Invitrogen) supplemented with 10% FBS, 0.1 mM nonessential amino acids, 1% penicillin-streptomycin, and 25 mM HEPES. When specified, TC-core–infected cells were incubated with DMSO, sunitinib (4 μM), or erlotinib (10 μM) beginning at 24 hours after infection. Time-lapse images were taken using a Leica SP5 II AOBS Tandem Scanner Spectral confocal microscope with a ×100 1.46 oil objective and a heated (37°C) chamber. An average of 5 movies representing individual cells with 15–30 trackable puncta each were recorded per sample with sequential frames taken every 2 seconds. Individual core puncta run lengths and transport velocities were calculated using the Manual Tracking plug-in for ImageJ, measuring the distance traveled (in any direction) between frames for a respective TC-core puncta.

Resistance studies. DENV4 (BC287/97; ATCC/BEI Resources, BEI NR-3806) was used to inoculate Huh7 cells at MOI of 0.01 and passaged every 3 days by transferring of an equal volume of viral supernatant to naive cells under increasing drug selection (0.5–1.5 μM, passages 1–6; 2.5 μM, passages 7 and 8). Upon completion of 8 passages, virus from the resulting supernatants was titered by plaque assays. SDM25N resistance mutation in NS4B at passage 8 was confirmed by purification and reverse transcription of viral RNA from supernatants of cells treated with DMSO or SDM25N as described in the RNA extraction and quantification section. NS4B region was amplified with iProof high-fidelity PCR kit (Bio-Rad) using primers NS4B forward GAT-GTGGAYYTGAGACCAGCYTCAGCATGGAC and NS4B reverse AGTCAAANACTTCAGAAAGCCCTATGTGTTCATCA (N = any base, Y = C or T) and sequenced (Sequestech Corp.).

In vivo dengue studies. AG-129 mice deficient in type I and II IFN receptors were obtained from Harry Greenberg (Stanford University, Stanford, California, USA). Mice were backcrossed to C57Bl/6 if n = 10 generations to obtain congenic AG-B6 strain. Age-matched, male and female mice at 8–10 weeks of age were used for all experiments. Mouse-adapted N124D/K128E DENV2 (5 × 10^4 PFU) produced in BHK-21 cells or 10^5 PFU produced in C6/36 cells) was inoculated retro-orbitally into mice under general and local anesthesia. Drugs were administered at the indicated doses in a total volume of 100–200 μl per animal using 10% Captisol as vehicle. Drugs or vehicle were administered i.p. or orally once or twice daily starting at the time of inoculation or at various time points after inoculation for a total of 3–5 days. Mice were monitored twice daily until the conclusion of the experiment. Moribund animals were euthanized by carbon dioxide inhalation. Serum was isolated from whole blood harvested retro-orbitally at 48 or 72 hours after DENV inoculation under general and local anesthesia. Tissues were harvested following euthanasia and snap-frozen on dry ice until further analysis.

In vivo Ebola studies. Groups of 10 female C57BL/6 mice (8–12 weeks of age) purchased from Jackson Laboratory were treated with drugs or vehicle 6 hours before viral challenge. Erlotinib and sunitinib...
were administered i.p. at the indicated doses in a total volume of 200 μl using 10% Capsitol as vehicle. A group of 10 mice was left untreated to allow for interpretation of any survival seen in the vehicle-treated group. Mice were inoculated i.p. with 100 PFU of mouse-adapted EBOV. Mice were then treated once daily for a total of 10 days and observed daily for 28 days for lethality or clinical signs of disease.

**RNA extraction and quantification.** Total RNA from cells was isolated using an RNA purification kit (Macherey-Nagel). Mouse serum was purified from whole blood using Terumo Capijet Capillary Blood collection tubes (Thermo Fisher Scientific). Tissues were homogenized using 0.9- to 2-mm stainless steel beads in a BBX24 Bullet Blender homogenizer (NextAdvance). Total RNA from serum and tissues was extracted with QIAamp UltraSens Virus kit (Qiagen). cDNA was generated using a high-capacity cDNA reverse transcription kit (Invitrogen). DENV RNA was quantified by qRT-PCR using TaqMan GEX master mix (Thermo Fisher Scientific), and AAKI, GAK, EBOV GP, and housekeeping gene (GAPDH) RNA was quantified using Taq Universal SYBR Green Supermix (Bio-Rad) on a StepOnePlus real-time PCR system (Applied Biosystems). Primer and probe sequences are as follows: DENV2 forward, CAGAAGCTTCTGGTGATGCAGA; DENV2 reverse, ACTGTGTCACAGTCGAGA; DENV2 probe, TATGCCTAAACGCCAGGAACCGC; GAPDH forward, GAAATCCCATCACCATCTTCCAG; GAPDH reverse, GAGCCCCAGCCTTCTCCATG.

**Viability assays.** Viability was assessed using alamarBlue reagent (Invitrogen) according to the manufacturer’s protocol. Fluorescence was detected at 560 nm on an InfiniteM1000 plate reader (Tecan).

**Data analysis of combination drug treatment.** Synergy/antagonism analysis was performed using the MacSynergy II program as previously described (23, 73). Matrix data sets in 4 replicates were assessed at the 95% confidence level for each experiment. Synergy and log volume were calculated. As suggested by Prichard et al. (73), such data sets should be interpreted as follows: volumes of synergy or antagonism at values less than 25 μM% are insignificant, those of 25–50 μM% are minor but significant, those of 50–100 μM% are moderate and probably important in vivo, and those of greater than 100 μM% are strong and likely to be important in vivo.

**Statistics.** All data were analyzed with GraphPad Prism software. Fifty percent effective concentrations (EC₅₀) were measured by fitting of data to a 3-parameter logistic curve. P values were calculated by 2-tailed unpaired t test and 1- or 2-way ANOVA with either Dunnett’s or Tukey’s multiple comparisons tests for in vitro data sets and by Mann-Whitney test for in vivo data sets as specified in each figure legend. Survival curve P values were calculated by log-ranked Mantel-Cox test.

**Study approval.** Animal research was conducted under a protocol approved by Stanford’s IACUC (Administrative Panel on Laboratory Animal Care) and its Institutional Biosafety Committee (Administrative Panel on Biosafety) or by the US Army Medical Research Institute of Infectious Diseases (USAMRIID) IACUC in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals. The Stanford and USAMRIID animal facilities are AAALAC-accredited and adhere to the principles stated in the 2005 Guide for the Care and Use of Laboratory Animals (National Academies Press). DENV and EBOV challenge studies were conducted in a biosafety level 2 (BSL-2) and a maximum-containment BSL-4 facility, respectively. Moribund mice were humanely euthanized on the basis of IACUC-approved criteria.

**Author contributions**

SE, EB, GN, AS, SYP, JB, RBB, JG, MSD, JMD, and GR conceived and designed the experiments. EB, GN, AS, SYP, JB, SW, FX, RBB, JG, RBB, and CMN performed the experiments. SE, EB, GN, AS, SYP, JB, SW, FX, RBB, JG, MSD, JMD, and GR analyzed the data. RM, CMN, SD, and PH contributed reagents/materials/models. EB and SE wrote the manuscript. SE supervised the overall project.

**Acknowledgments**

This work was supported by award 1U19 AI10966201 (Centers of Excellence for Translational Research) from the National Institute of Allergy and Infectious Diseases (NIAID) to SE, NIAID U19 AI083019 to MSD, grant RSG-14-11-0-01-MPC from the American Cancer Society to SE and GR, and grants from Stanford Bio-X, the Stanford SPARK program, and the Stanford Translational Research and Applied Medicine program. In vitro studies were also supported by grant 2013100 from the Doris Duke Charitable Foundation and grant PR151090 from the Department of Defense office of the Congressionally Directed Medical Research Programs. GN was supported by the Child Health Research Institute, Lucile Packard Foundation for Children’s Health, as well as the Stanford Clinical and Translational Science Award (CTSA, grant UL1 TR000093). SYP was supported by Taiwan Ministry of Science and Technology grant 103-2917-I-564-033. JMD’s work acknowledges the support of the Joint Science and Technology Office-Defense Threat Reduction Agency (CB3958) in completion of the live virus experiments. The opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the US Army or the other funders. We thank Scott Weaver and Robert Tesh for the ZIKV (MR766), Mark N. Prichard for providing the MacSynergy II program, Kartik Chandran for the rVSV-GP EBOV construct, Eva Harris and Karla Kirkegaard for assistance with establishing dengue tissue culture and mouse models in our laboratory, and Alex McMillan (with support from CTSA UL1 TR001085) for assistance with the statistical analysis.

Address correspondence to: Shirir Einav, Department of Medicine, Stanford University, 300 Pasteur Drive, Lane Building L127, Stanford, California 94305, USA. Phone: 650.723.8656; E-mail: seinav@stanford.edu.

GN’s present address is: International Center for Infectiology Research, Université de Lyon; Inserm, U1111; Ecole Normale Supérieure de Lyon; Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie; LabEx Ecofect, Université de Lyon, Lyon, France.

4. Dejnirattisai W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhance-
The Journal of Clinical Investigation

Research Article


